PET-RTRC
Resources
To learn more about current Technology Researcher & Development (TR&D) projects, to request the formation of a Collaborative Project (CP) or Service Project (SP), or to find contact information for the principal investigators of each project, go to PET-RTRC Projects.
Radiopharmaceuticals
The PET-RTRC offers a variety of novel radiopharmaceuticals under the Collaborative Projects (CP) and Service Projects (SP) mechanisms. These include specific agents 11C-TZ3321 (S1P1) and 64Cu-DOTA-ECL1i, which target inflammation, and novel 68Ga based imaging agents that target ROS-mediated Oxidative Stress.
If you have any questions or to learn more about how these agents can be used to further your research goals, email Michelle Hoelscher.
All Radiopharmaceuticals and Radiochemicals listed below are prepared in-house using the MIR Cyclotron Facility & Nuclear Pharmacy. This list is not comprehensive, but does highlight the compounds available. For additional information on any of the products listed below, email Michael Nickels, PhD.
| Compound w/ Isotope | Typical Utilization |
|---|---|
| [F-18] FDG* (Fluorodeoxyglucose) | Imaging agent of glucose uptake, making it useful for imaging tumors. It is the standard imaging agent used in PET for cancer patient management |
| [F-18] FLT* (Fluorodeoxythymidine) | Indicated use to image cellular proliferation, FLT is a nucleoside analog that accumulates in proliferating cells. May validate the efficacy of chemotherapy in patients with lymphoma and other cancers. |
| [F-18] FFNP* (Fluorofurylmethylidene dioxynorpregnenedione) | Indicated use as an imaging agent that binds to progesterone receptors (PgR) in progesterone-responsive tissues. In PgR-positive breast cancer, it may be used to quantitate hormone receptor status. |
| [F-18] ISO-1* (Sigma-1) | Indicated use as a promising imaging agent for evaluation of the proliferative status of solid tumors. |
| [F-18] NOS* (Nitric oxide synthase) | Used to evaluate the feasibility of imaging cellular iNOS activity. |
| [F-18] VAT* | Indicated use to quantify the vesicular acetylcholine transporters in the brain synapses in the central nervous system CNS. |
| [F-18] FES* (Fluoroestradiol) | Indicated use as an imaging agent of estrogen receptor content in breast tumors. |
| [F-18] FTT* (FluorThanatrace) | An imaging agent of PAR activity that may aid in the selection of patients that will benefit from PARP inhibition treatments. |
| [F-18] AV-1451* & [F-18] MK6240* | Inquire about availability. |
| [F-18] NaF | Imaging of bone abnormalities. |
| [F-18] FDOPA* (Fluorodopa)(Nucleophilic) | Indicated use as imaging agent of movement disorders, and brain malignancies. It may also be useful for imaging other malignant diseases such as neuroendocrine tumors, pheochromocytoma and pancreatic adenocarcinoma. |
| [C-11]PIB* (Pittsburgh Compound B) | Indicated uses as an amyloid imaging agent |
| [C-11] CHO* (Choline) | Imaging agent used to detect sites of prostate cancer that have returned despite treatment (recurrent prostate cancer). It may be used when other imaging has not been helpful. |
| [C-11] Palmitate* | Palmitate is the most accurate method to measure myocardial fatty acid metabolism, permitting measurement of fatty acid uptake, oxidation and storage. |
| [C-11] PKAB* | An antagonist imaging agent for Kappa opioid receptor. |
| [C-11] Raclopride* | Indicated use as reversible imaging agent of D2/3 receptors. |
| [C-11] Acetate* | Myocardial metabolism and indicated use as a tumor imaging agent in prostate cancer. |
| [C-11] MHED | Sympathetic nervous system imaging. Targets the norepinephrine transporter. |
| [C-11] S1P1* | [11C] TZ3321 used to assess the inflammation response that will not have genetic phenotype limitation. |
| [C-11] NMB* | Indicated use as an imaging agent for D2 receptors. |
| [N-13] Ammonia* | Indicated use for diagnostic Posit imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. |
| [O-15] Water* | Indicated use as an imaging agent of blood flow. Because it is washed out in proportion to the regional blood flow and its kinetics are not affected by metabolism it can be used to assess blood flow. |
| [O-15] Gases (O2, CO)* | Inhalation of [15O]O2 and [15O]CO measure oxygen consumption and blood volume. |
| [Cu-64] LLP2A* | Imaging of myeloma. |
| [Cu-64] ATSM | Imaging of hypoxia. |
| [Zr-89] Herceptin* | HER2 positive breast cancer imaging agent. |
* compound is available for human use
All Radiochemicals listed below are available on-demand and can be shipped to facilities with active radiation approvals. For additional information on any of the radiochemicals listed below, email Tom Voller.
- [Cu-64] Copper Chloride (API Grade under DMF)
- [Cu-64] Copper Chloride (Radiochemical Grade)
- [Zr-89] Zirconium Oxalate
- [Br-76] Bromide
- [Ga-68] Gallium Chloride
Quantitative Imaging Informatics Resource (QI2R)
The QI2R was established to:
- ensure standardized evaluation of radiotracer performance
- facilitate the movement and management of data throughout the PET-RTRC
The QI2R has two primary functions:
- quantitative image analysis of Center image datasets
- development and management of informatics pipelines
The QI2R will provide guidance and expertise in quantitative imaging to be employed by TR&Ds. In doing so, the QI2R will promote standardized/unified image analytics across Center activities and promote training of Center members.
The QI2R will develop and implement advanced quantitative imaging pipelines to characterize radiotracer performance.
To facilitate the movement and management of data throughout the Center, the QI2R developed the co-clinical database (CCDB). The CCDB is built on XNAT, a widely used open-source imaging informatics platform. XNAT is a web-based software platform designed to facilitate common management and productivity tasks for imaging and associated data. A fine-grained access control system ensures that users are restricted to accessing only authorized data. XNAT also includes a web services API for programmatic access and a plugin architecture for extending XNAT’s core capabilities. For QI2R, data contributors will upload Center-related data and metadata to the CCDB using a secure web application. Data will be organized in study-specific projects that provide access to authorized personnel.
For more information please email Michelle Hoelscher
Technology Training and Dissemination
Training is available for PET radiochemists and radiopharmacists to synthesize radiotracers produced by the PET-RTRC and scientists who use this technology. We provide opportunities for interested researchers, such as basic scientists with training in preclinical imaging using PET radiotracers and clinician scientists in the design and conduct of human research studies using PET as an imaging modality.
- Individualized hands-on training is available
- 2-3 month lead time is needed
- For more information please email Michelle Hoelscher
February 22, 2023
Multi-Modality and Molecular Imaging of Cardiac Injury and Remodeling: Emerging Role of Theranostics
Albert Sinusas, MD, FACC, FAHA
Yale University School of Medicine
August 12, 2022
In Vivo Quantitative Mapping of Cardiac Membrane Potential
Georges el Fakhri, PhD, DABR
Massachusetts General Hospital, Harvard Medical School
August 31, 2021
Design of Tumor Targeting Tracers
Uwe Haberkorn, MD, PhD
Heidelberg University
April 23, 2021
PARP-1 Radiotracers for PET Imaging and Small Molecule Targeted Alpha Radiotherapeutics
Robert H. Mach, PhD
University of Pennsylvania, Perelman School of Medicine
December 2, 2020
Pinpointing the Site of Pain Generation Using PET MRI
Sandip Biswal, MD
Stanford University School of Medicine
September 9, 2020
Tracking Dynamic Immune Activation and Invasion in Neurological Diseases Using PET
Michelle L. James, PhD
Stanford University School of Medicine
June 17, 2020
Annotating Cancer Biology Through Molecular Imaging
Jason S. Lewis, PhD
Memorial Sloan Kettering Cancer Center
Standardized Procedures (SOPs)
For optimal evaluation of radiotracer performance, Standardized Procedures are available upon request.
For more information please email Michelle Hoelscher.
Annual Workshops and Scientific Sessions
Regulatory Workshop
USP Chapter 823 Production of PET Radiopharmaceuticals for Research Use
Sally Schwarz, RPh, BCNP
Washington University School of Medicine
Aseptic Training and Quality Assurance
Reiko Oyama, RPh, BCNP
Washington University School of Medicine
CMC Preparation for Research Radiopharmaceuticals
Stephen Moerlein, PharmD, PhD
Washington University School of Medicine
Toxicology for IND or eIND submission
Kelly Long, MS, DABT
Inotiv
IND Dosimetry Overview
Richard Laforest, PhD
Washington University School of Medicine
IND Application: The Preparation and Assembly Process- Clinical Protocol, Consent Form, CMC, Toxicology and Dosimetry
Deborah Koudelis, RN, MS
Washington University School of Medicine
FDA Audit Handling
Michael Nickels, PhD
Washington University School of Medicine
Theranostics Workshop
Recent Progress in Radiotheranostics – Focus on Alpha Emitters
Richard Wahl, MD
Washington University School of Medicine
Theranostic Research of Neuroendocrine Neoplasms
Vikas Prasad, MD
Washington University School of Medicine
Specific Considerations for QC of Actinium-225 Radiopharmaceuticals and Other Alpha-Emitting Isotopes
Diane Abou, PhD
Washington University School of Medicine
Implementing a Radiopharmaceutical Therapy Program
Jacqueline E. Zoberi, PhD
Washington University School of Medicine
Working with Industry from a Theranostics Perspective
Elyse Koester, CNMT, MBA
Michael Nickels, PhD
Washington University School of Medicine
Late Phase and Commercial Considerations for a Therapeutic Radiopharmaceutical
Kevin Staton – VP CDMO Projects
Evergreen Theragnostics, Inc
64Cu/67Cu Chemistry and Utilization
Michael Nickels, PhD
Washington University School of Medicine
Scientific Session
The Orthotopic Lung Transplant Model for the Development of Non-Invasive Methods to Monitor Lung Inflammation
Andrew E. Gelman, PhD
Washington University School of Medicine
Oxidative Stress in Neurodegenerative Diseases
Erik Musiek, MD, PhD
Washington University School of Medicine
Imaging Neuroinflammation in Parkinson Disease
Joel Perlmutter, MD
Washington University School of Medicine
Imaging Innate and Adaptive Immune Responses in Multiple Sclerosis
Caroline Guglielmetti, PhD
Washington University School of Medicine
Preclinical Imaging Workshop
Advances and Applications in Preclinical CT
Cristian Badea, PhD
Duke University
Quantitative Assays
Part 1: Jinbin Xu, PhD
Part 2: Hao Jiang, PhD
Washington University School of Medicine
Quantitative Imaging Computational Modeling
Part 1: Abhinav Jha, PhD
Part 2: Ganesh Chand, PhD
Washington University School of Medicine
Imaging of Non-Human Primates
Joel Perlmutter, MD
Washington University School of Medicine
Quantitative Neuroimaging in NHP
Richard Carson, PhD
Yale University
Preclinical Theranostics
Daniel Thorek, PhD
Washington University School of Medicine
Antibody Radiopharmaceuticals for Cancer Imaging and Therapy
Patrícia Ribeiro Pereira, PhD
Washington University School of Medicine
STTR Experience
Monica Shokeen, PhD
Washington University School of Medicine
Clinical Imaging Workshop
Translating Radiotracers into Human Subjects: Lessons Learned
Part 1: Pamela Woodard, MD
Part 2: Farrokh Dehdashti, MD
Washington University School of Medicine
Current and Future State of PET Imaging Agents
Part 1: Robert Gropler, MD
Part 2: Amir Iravani, MD
Part 3: Tammie Benzinger, MD, PhD
Washington University School of Medicine
Human Dosimetry and Radio-Metabolite Analysis
Part 1: Richard Laforest, PhD
Part 2: Michael Nickels, PhD
Washington University School of Medicine
Current and Future State of Theranostics
Part 1: David Mankoff, MD, PhD
Penn Medicine
Part 2: Richard Wahl, MD
Washington University School of Medicine
Patient Enrollment and FDA Reporting
Part 1: Deborah Koudelis, RN, MS
Part 2: Jennifer Frye, CNMT
Washington University School of Medicine
Working with Industry – Academic and Industry Perspectives
Part 1: Elyse Koester, MBA, CNMT
Washington University School of Medicine
Part 2: Darcy Denner, PhD
Curium, St. Louis, MO
Radiometal Labeling Workshop
Cyclotron Facility Design and Regulatory
Michael Nickels, PhD
Washington University School of Medicine
Cyclotron Production of Metal and Non-metal Isotopes
Michael Nickels, PhD
Washington University School of Medicine
Purification of Radiometal Isotopes
David Reichert, PhD
Washington University School of Medicine
Chemistry of PET Radiometal Isotopes
Buck Rogers, PhD
Washington University School of Medicine
Radiometal Labeling of Peptides and Antibodies and their Preclinical Evaluation
Jason Lewis, PhD
Memorial Sloan Kettering
GMP Production with Radiometals
Sally Schwarz, RPh
Washington University School of Medicine
Chemistry of Standard Radionuclides Workshop
F-18 Chemistry
Steven Liang, PhD
Massachusetts General Hospital
O-15 and N-13 Human Use Logistics
Greg Gaehle
Washington University School of Medicine
C-11 Chemistry
Zhude Tu, PhD
Washington University School of Medicine
Quality Control of Isotopes and Products
Henry VanBrocklin, PhD
University of California, San Francisco
Automation for Isotope Utilization
Michael Nickels, PhD
Washington University School of Medicine
Clinical Utilization of Metal and Non-Metal Isotopes
Amir Iravani, MD
Washington University School of Medicine
Research Output
Efforts by the PET-RTRC since its inception have yielded a number of publications, patents and licenses.
| Title | Authors | Journal | Project | Joint Investigations and Interactions (Collaborative & Service Projects |
|---|---|---|---|---|
| Ketosis Prevents Abdominal Aortic Aneurysm Rupture Through CCR2 Downregulation and Enhanced MMP Balance | Sastriques-Dunlop S, Elizondo-Benedetto S, Arif B, Meade R, Zaghloul MS, English SJ, Liu Y, Zayed MZ | bioRxiv.2023 Feb 22;2023.02.21.529460. doi: 10.1101/2023.02.21.529460 | TR&D 2 | CP- Zayed |
| Targeting Immune-Fibroblast Crosstalk in Myocardial Infarction and Cardiac Fibrosis | Lavine K, Amrute J, Luo X, Penna V, Bredemeyer A, Yamawaki T, Yang S, Kadyrov F, Heo G, Shi S, Lee P, Koenig A, Kuppe C, Jones C, Kopecky B, Hayat S, Ma P, Terada Y, Fu A, Furtado M, Kreisel D, Stitziel N, Li CM, Kramann R, Liu Y, Ason B | Res Sq. 2023 Jan 26;rs.3.rs-2402606.doi: 10.21203/rs.3.rs-2402606/v1 | TR&D 2 | CP- Lavine SP- Kriesel |
| Positron Emission Tomography Imaging of Vessel Wall Matrix Metalloproteinase Activity in Abdominal Aortic Aneurysm | Toczek J, Gona K, Liu Y, Ahmad A, Ghim M, Ojha D, Kukreja G, Salarian M, Luehmann H, Heo GS, Guzman RJ, Chaar CIO, Tellides G, Hassab AHM, Ye Y, Shoghi KI, Zayed MA, Gropler RJ, Sadeghi MM | Circ Cardiovasc Imaging. 2023 Jan;16(1):e014615 | TR&D 2 QI2R | CP- Zayed |
| Nuclear Methods for Immune Cell Imaging: Bridging Molecular Imaging and Individualized Medicine | Heo GS, Diekmann J, Thackeray JT, Liu Y | Circ Cardiovasc Imaging. 2023 Jan;16(1):e014067 | TR&D 2 | |
| Blocking CHOP-dependent TXNIP shuttling to mitochondria attenuates albuminuria and mitigates kidney injury in nephrotic syndrome | Park SJ, Kim Y, Li C, Suh J, Sivapackiam J, Goncalves TM, Jarad G, Zhao G, Urano F, Sharma V, Chen YM. | Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2116505119 | TR&D 3 | |
| Cardiac Immune Cell Infiltration Associated with Abnormal Lipid Metabolism | Cifarelli V, Kuda O, Yang K, Liu X, Gross RW, Pietka TA, Heo GS, Sultan DH, Luehmann H, Lesser J, Ross M, Goldberg IJ, Gropler RJ, Liu Y, Abumrad NA. | Front Cardiovasc Med. 2022 Aug 17;9:948332. | TR&D 2 | SP- Abumrad/ Cifareli |
| The dynamic cardiac cellular landscape: visualization by molecular imaging | Lavine KJ, Liu Y. | Nat Rev Cardiol. 2022 Jun;19(6):345-347 | TR&D 2 | CP- Lavine |
| Radiosynthesis and evaluation of a fluorine-18 radiotracer [(18)F]FS1P1 for imaging sphingosine-1-phosphate receptor 1 | Qiu L, Jiang H, Yu Y, Gu J, Wang J, Zhao H, Huang T, Gropler RJ, Klein RS, Perlmutter JS, Tu Z. | Org Biomol Chem. 2022 Feb 2;20(5):1041-1052 | TR&D 2 | CP- Perlmutter |
| Solving the Conundrum of Eosinophils in Alloimmunity | Lynch CA, Guo Y, Mei Z, Kreisel D, Gelman AE, Jacobsen EA, Krupnick AS. | Transplantation. 2022 Aug 1;106(8):1538-1547 | TR&D 3 | SP- Kreisel |
| Phase 1 Evaluation of 11C-CS1P1 to Assess Safety and Dosimetry in Human Participants | Brier MR, Hamdi M, Rajamanikam J, Zhao H, Mansor S, Jones L, Rahmani F, Jindal S, Koudelis D, Perlmutter J, Wong DF, Nickels M, Ippolito J, Gropler RJ, Schindler TH, Laforest R, Tu Z, Benzinger T. | J Nucl Med. 2022 Mar 24:jnumed.121.263189 | TR&D 1 QI2R | SP- Brier CP- Perlmutter |
| Differential Sphingosine-1-Phosphate Receptor-1 Protein Expression in the Dorsolateral Prefrontal Cortex Between Schizophrenia Type 1 and Type 2 | Chand GB, Jiang H, Miller JP, Rhodes CH, Tu Z, Wong DF. | Front Psychiatry. 2022 Mar 8; 13:827981 | TR&D 1 | |
| Reprogramming Alveolar Macrophage Responses to TGF-ß Reveals CCR2+ Monocyte Activity that Promotes Bronchiolitis Obliterans Syndrome | Liu Z, Liao F, Zhu J, Zhou D, Heo GS, Luehmann HP, Scozzi D, Parks A, Hachem R, Byers D, Tague LK, Kulkarni HS, Cano M, Wong BW, Li W, Huang HJ, Krupnick AS, Kreisel D, Liu Y, Gelman AE | J Clin Invest. 2022 Oct; 132(19):e159229 | TR&D 2 | SP- Kreisel |
| Synthesis and evaluation of highly selective quinazoline-2,4-dione ligands for sphingosine-1-phosphate receptor 2 | Luo Z, Liu H, Yu Y, Gropler RJ, Klein RS, Tu Z. | RSC Med Chem. 2022 Jan 3;13(2):202-207 | TR&D 1 | |
| In Vitro and In Vivo Investigation of S1PR1 Expression in the Central Nervous System Using [(3)H]CS1P1 and [(11)C]CS1P1 | Jiang H, Joshi S, Liu H, Mansor S, Qiu L, Zhao H, Whitehead T, Gropler RJ, Wu GF, Cross AH, Benzinger TLS, Shoghi KI, Perlmutter JS, Tu Z. | ACS Chem Neurosci. 2021 Oct 6;12(19):3733-3744 | TR&D 1 QI2R | CP- Perlmutter |
| PET study of sphingosine-1-phosphate receptor expression in response to S. aureus infection | Jiang H, Gu J, Zhao H, Joshi S, Perlmutter JS, Gropler RJ, Klein RS, Benzinger TLS, Tu Z. | Mol Imaging. 2021 Oct 4;2021:9982020 | TR&D 1 | CP- Perlmutter |
| Resident Cardiac Macrophages Mediate Adaptive Myocardial Remodeling | Wong NR, Mohan J, Kopecky BJ, Guo S, Du L, Leid J, Feng G, Lokshina I, Dmytrenko O, Luehmann H, Bajpai G, Ewald L, Bell L, Patel N, Bredemeyer A, Weinheimer CJ, Nigro JM, Kovacs A, Morimoto S, Bayguinov PO, Fisher MR, Stump WT, Greenberg M, Fitzpatrick JAJ, Epelman S, Kreisel D, Sah R, Liu Y, Hu H, Lavine KJ | Immunity. 2021 Sep 14;54(9):2072-2088.e7 | TR&D 2 | CP- Lavine SP- Kreisel |
| Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases | Fox GC, Su X, Davis JL, Xu Y, Kwakwa KA, Ross MH, Fontana F, Xiang J, Esser AK, Cordell E, Pagliai K, Dang HX, Sivapackiam J, Stewart SA, Maher CA, Bakewell SJ, Fitzpatrick JAJ, Sharma V, Achilefu S, Veis DJ, Lanza GM, Weilbaecher KN. | Mol Cancer Ther. 2021 Jun;20(6):1183-1198 | TR&D 3 | |
| Spatially constrained kinetic modeling with dual reference tissues improves (18)F-flortaucipir PET in studies of Alzheimer disease | Zhou Y, Flores S, Mansor S, Hornbeck RC, Tu Z, Perlmutter JS, Ances B, Morris JC, Gropler RJ, Benzinger TLS. | Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3172-3186 | TR&D 1 | CP- Perlmutter |
| CXCR4-Binding Positron Emission Tomography Tracers Link Monocyte Recruitment and Endothelial Injury in Murine Atherosclerosis | Baba O, Huang LH, Elvington A, Szpakowska M, Sultan D, Heo GS, Zhang X, Luehmann H, Detering L, Chevigne A, Liu Y, Randolph GJ. | Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):822-836 | TR&D 2 | CP- Randolph |
| Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial | Brody SL, Gunsten SP, Luehmann HP, Sultan DH, Hoelscher M, Heo GS, Pan J, Koenitzer JR, Lee EC, Huang T, Mpoy C, Guo S, Laforest R, Salter A, Russell TD, Shifren A, Combadiere C, Lavine KJ, Kriesel D, Humphreys BD, Rogers BE, Gierada DS, Byers DE, Gropler RJ, Chen DL, Atkinson JJ, Liu Y. | Am J Respir Crit Care Med. 2021 Jan 1; 203(1): 78-89 | TR&D 2 QI2R | CP- Brody CP- Lavine |
| Targeted PET Imaging of Chemokine Receptor 2-Positive Monocytes and Macrophages in the Injured Heart | Heo GS, Bajpai G, Li W, Luehmann HP, Sultan DH, Dun H, Leuschner F, Brody SL, Gropler RJ, Kreisel D, Lavine KJ, Liu Y. | J Nucl Med. 2021 Jan;62(1):111-114 | TR&D 2 | CP- Brody CP- Lavine SP- Kreisel |
| Consensus Recommendations on the Use of (18)F-FDG PET/CT in Lung Disease | Chen DL, Ballout S, Chen L, Cheriyan J, Choudhury G, Denis-Bacelar AM, Emond E, Erlandsson K, Fisk M, Fraioli F, Groves AM, Gunn RN, Hatazawa J, Holman BF, Hutton BF, Iida H, Lee S, MacNee W, Matsunaga K, Mohan D, Parr D, Rashidnasab A, Rizzo G, Subramanian D, Tal-Singer R, Thielemans K, Tregay N, van Beek EJR, Vass L, Vidal Melo MF, Wellen JW, Wilkinson I, Wilson FJ, Winkler T. | J Nucl Med. 2020 Dec;61(12):1701-1707 | TR&D 1 | |
| Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors | Tangadanchu TKR, Jian H, Yu Y, Graham THA, Liu H, Rogers BE, Gropler RJ, Perlmutter J, Tu Z. | Eur J Med Chem. 2020 Nov 15;206:112713 | TR&D 1 | CP- Perlmutter |
| Delineating the Role of Macrophages in Cardiovascular Disease: How Specific Do We Need to Be? | Liu Y, Gropler RJ. | Circ Cardiovasc Imaging. 2020 Oct;13(10):e011605 | TR&D 2 | |
| Galuminox: Preclinical validation of a novel PET tracer for non-invasive imaging of oxidative stress in vivo | Sivapackiam J, Liao F, Zhou D, Shoghi KI, Gropler RJ, Gelman AE, Sharma V. | Redox Biol. 2020 Oct;37:101690 | TR&D 3 QI2R | |
| In vivo Characterization of Four (18)F-Labeled S1PR1 Tracers for Neuroinflammation | Liu H, Luo Z, Gu J, Jiang H, Joshi S, Shoghi KI, Zhou Y, Gropler RJ, Benzinger TLS, Tu Z. | Mol Imaging Biol. 2020 Oct;22(5):1362-1369 | TR&D 1 QI2R | |
| Preclinical PERCIST and 25% of SUV(max) Threshold: Precision Imaging of Response to Therapy in Co-clinical (18)F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts | Savaikar MA, Whitehead T, Roy S, Strong L, Fettig N, Prmeau T, Luo J, Li S, Wahl RL, Shoghi KI. | J Nucl Med. 2020 Jun;61(6):842-849 | QI2R | |
| Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy | Peterson LR, Gropler RJ. | Circ Res. 2020 May 22;126(11):1628-1645 | TR&D 2 | |
| Myeloid-specific Asxl2 deletion limits diet-induced obesity by regulating energy expenditure | Zou W, Rohatgi N, Brestoff JR, Moley JR, Li Y, Williams JW, Alippe Y, Pan H, Pietka TA, Mbalaviele G, Newberry EP, Davidson NO, Dey A, Shoghi KI, Head RD, Wickline SA, Randolph GJ, Abumrad NA, Teitelbaum SL. | J Clin Invest. 2020 May 1;130(5):2644-2656 | QI2R | CP- Randolph SP- Abumrad/ Cifarelli |
| Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [(11)C]CS1P1 | Liu H, Laforest R, Gu J, Luo Z, Jones LA, Gropler RJ, Benzinger TLS, Tu Z. | Mol Imaging Biol. 2020 Apr;22(2):285-292 | TR&D 1 QI2R | |
| CCR2 Positron Emission Tomography for the Assessment of Abdominal Aortic Aneurysm Inflammation and Rupture Prediction | English SJ, Sastriques SE, Detering L, Sultan D, Luehmann H, Arif B, Heo GS, Zhang X, Laforest R, Zheng J, Lin CY, Gropler RJ, Liu Y. | Circ Cardiovasc Imaging. 2020 Mar;13(3):e009889 | TR&D 2 QI2R | CP- Zayed |
| Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [(11)C]CS1P1 for human use | Luo Z, Gu J, Dennett RC, Gaehle GG, Perlmutter JS, Chen DL, Benzinger TLS, Tu Z. | Appl Radiat Isot. 2019 Oct;152:30-36 | TR&D 1 | CP- Perlmutter |
| Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor | Luo Z, Liu H, Klein RS, Tu Z. | Bioorg Med Chem. 2019 Aug 15;27(16):3619-3631 | TR&D 1 | |
| Molecular Imaging Visualizes Recruitment of Inflammatory Monocytes and macrophages to the Injured Heart | Heo GS, Kopecky B, Sultan D, Ou M, Feng G, Bajpai G, Zhang Z, Luehmann H, Detering L, Su Y, Leuschner F, Combadiere C, Kreisel D, Gropler RJ, Brody SL, Liu Y, Lavine KJ | Circ Res. 2019 Mar 15;124(6):881-890 | TR&D 2 | CP- Brody CP- Lavine SP- Kreisel |
| Syntheses and in vitro biological evaluation of S1PR1 ligands and PET studies of four F-18 labeled radiotracers in the brain of nonhuman primates | Luo Z, Han J, Liu H, Rosenberg AJ, Chen DL, Gropler RJ, Perlmutter JS, Tu Z. | Org Biomol Chem. 2018 Dec 5;16(47):9171-9184 | TR&D 1 | CP- Perlmutter |
- TR&D 1: Tu Z., Qiu L., Yu Y., Gu J., Gropler RH., T-019667 — F-18 radiochemistry and procedure of making F-18 labeled radiotracer [18F]CS1P1. Reference #DF-013541, submitted on January 26, 2021.
- TR&D 1: Zhude Tu, Lin Qui, Jiwei Gu, Yanbo Yu, and Robert Gropler, U.S. Provisional Patent Application No. 63/288,336 entitled Compositions For Binding Sphingosine-1-Phosphate Receptor 1 (S1p1), Imaging Of S1p1, And Processes For Preparation Thereof Wustl Case No. 019667/Us02, Stinson File Wstl 19667.Pro2 (3510075.010102)
- TR&D 3: “Compositions and methods for measuring oxidative stress.” Application # Application #17/344, 739. Publication No: US-2021-0386874-A1. Non-provisional patent application from 6/2021
Facility Support
In its effort to advance precision imaging, the PET-RTRC regularly utilizes the resources and services of three of MIR’s leading-edge facilities.
The CCIR assists PET-RTRC investigators and their collaborators in the basic and translational science imaging research studies. The facility is linked directly to the Cyclotron Facility & Nuclear Pharmacy by a pneumatic tube system for purposes of immediate unit-dose delivery of radiopharmaceuticals.
Learn more about the CCIR.
The Cyclotron Facility & Nuclear Pharmacy is instrumental to the PET-RTRC’s core mission of developing and disseminating novel PET radiotracers used in preclinical and human imaging studies. The facility’s director is Training and Dissemination co-leader Dr. Michael Nickels.
Learn more about the Cyclotron Facility & Nuclear Pharmacy.
The PET-RTRC utilizes an array of services from the Preclinical Imaging Facility, including multi-modality PET/CT imaging, simultaneous PET/MR imaging and Bioluminescence imaging of radioactive materials. The facility is directed by QI2R co-leaders Drs. Richard Laforest and Kooresh Shoghi.
Learn more about the Preclinical Imaging Facility.
